Chlornaphazine
From Self-sufficiency
| Chlornaphazine | |
|---|---|
| File:Chlornaphazine.png | |
| N,N-Bis(2-chloroethyl)naphthalen-2-amine | |
| Other names Chlornapazine; 2-Naphthylbis(chloroethyl)amine | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 494-03-1 |
| PubChem | 10307 |
| ChemSpider | 9885 |
| SMILES | Script error: No such module "collapsible list". |
| InChI | Script error: No such module "collapsible list". |
| InChI key | XCDXSSFOJZZGQC-UHFFFAOYAW |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C14H15Cl2N |
| Molar mass | 268.18 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Chlornaphazine, a derivative of 2-naphthylamine, is a nitrogen mustard that was developed in the 1950s for the treatment of polycythemia and Hodgkin's disease.[1] However, a high incidence of bladder cancers in patients receiving treatment with chlornaphthazine led to use of the drug being discontinued.[2]
The International Agency for Research on Cancer has listed chlornaphazine as a human carcinogen.[3]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />- ↑ Videbaek, A.; Kaae, S. (1954). "2-Naphthylbis(chloroethyl)amine in the treatment of malignant diseases, particularly Hodgkin's disease". Acta Medica Scandinavica. 149 (5): 361–368. doi:10.1111/j.0954-6820.1954.tb11446.x. PMID 13180246.
- ↑ Benedicte Laursen (1970). "Cancer of the Bladder in Patients Treated with Chlornaphazine". Br Med J. 3 (5724): 684–685. doi:10.1136/bmj.3.5724.684. PMC 1701774 Freely accessible. PMID 5470116.
- ↑ N,N-Bis(2-Chloroethyl)-2-Naphthylamine (Chlornaphazine), International Agency for Research on Cancer
